Search
Tacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. … It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex.
Products: Tacroz Ointment 0.1% w/w, TACROLIMUS MYLAN GENERICSCyclophosphamide
go.drugbank.com/drugs/DB00531ApprovedInvestigationalPrecursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide.
Oxtriphylline
go.drugbank.com/drugs/DB01303ApprovedIn the US, oxtriphylline is no longer available. … Its main physiological reponse is to dilate the bronchioles. As such, oxytriphylline is indicated mainly for asthma, bronchospasm, and COPD (i.e. all the same indications as the other theophyllines).
Remdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigationalSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia … [A222393] Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017,[A191382] leading to considerable interest in remdesivir as a possible treatment for COVID-19.
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnvoluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug. … It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalOn November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label].
Tasonermin
go.drugbank.com/drugs/DB11626ApprovedIt was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma
Trazodone
go.drugbank.com/drugs/DB00656ApprovedInvestigational[A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: 2-(3-[4-(3-chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-oneAvacincaptad pegol
go.drugbank.com/drugs/DB15165ApprovedInvestigationalAvacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule. … It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA).
Rosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRecent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. … Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action.
International brands: Sheng Ao